Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: A comparative study between the standard 4-dose and a 2-dose regimen

Bone Marrow Transplantation

Volumn 41, Issue 7, 2008, Pages 621-625

  Mellgren, K ^a   Nilsson, C ^b   Fasth, A ^a   Abrahamsson, J ^a   Winiarski, J ^b   Ringden O ^b   Hassan, M ^b  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GELATIN; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHILD; CHILD CARE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEPATOMEGALY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; INCIDENCE; INFANT; LEUKEMIA; LIVER BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SEIZURE; SOLID TUMOR; STEM CELL TRANSPLANTATION; SWEDEN; VEIN OCCLUSION; WEIGHT GAIN;

ADMINISTRATION, ORAL; BUSULFAN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; LEUKEMIA; MALE; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 42149126624     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705947     Document Type: Article

References (28)

1. Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab Dispos 1987; 15: 399-402.
2. Srivastava A, Poonkuzhali B, Shaji RV. George B, Mathews V, Chandy M et al. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclussive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577.
3. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y et al. Influence of glutathione S-transferase Al polymorphism on the pharmacokinetics of busulfan. Clin Chin Acta 2006; 368: 93-98.
4. Hassan M, Ljungman P, Bolme P, Ringden Q, Syrucková Z, Békàssy A et al.. Busulfan bioavaliability. Blood 1994; 84: 2144-2150.
5. Bullock JM, Smith PF, Booker BM, Loughner J, Capozzi D, McCarthy Jr PL et al. Development of a pharmacokinetic and, Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 2006; 28: 62-66.
6. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: Does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 156-165.
7. Bolinger, AM, Zangwill, AB, Slattery JT, Risler U, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013-1018.
8. Sandstrom M, Karlsson MO, Ljungman P, Hassarf Z, Jonsson EN, Nilsson C, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphap in bone, marrow transplantation recipients. Bone Marrow Transplant 2001; 28: 657-664.
9. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, van dep Berg H et al. Busulphan Kinetics and limited sampling, model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18; 843-850.
10. Bolinger, AM; Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L et al. An evaluation of engagement, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease, Bone Marrow Transplant, 2000. 25 925-930.
11. Slattery JT, Clift RA, Bukner CD, Radich J, Storer B, Bensigger WI et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation: Blood 190; 89: 3055-3060.
12. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
13. Vassal G, Hartmann O, Benhamou E. Busulfan and veno-occlussive disease of the liver. Ann Intern Med 1990; 112: 881.
14. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R et al Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
15. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
16. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35 17-23.
17. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Mellgren K, Fasth A, Saalman R, Olausson M, Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol 2005; 84: 755-757.
20. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746-750.
21. Mc Donald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
22. DeLeve LD. Glutathione defense in non-parenchymal cells. Semin Liver Dis 1998; 18: 403-413.
23. Jenke A, Freiberg-Richter J, Wilhelm S, Freund M, Renner UD, Bornhäuser M et al. Accidental busulfan overdose during conditioning for stem cell transplantation. Bone Marrow Transplant 2005; 35: 125-128.
24. Petersen FB, Sanders JE, Storb R, Bensinger WI, Clift RA, Buckner CD. Inadvertent administration of a greater-than-usual. pre-marrow transplant dose of busulfan - report, of a case. Transplantation 1988; 45: 821-822.
25. Stein J, Davidovitz M, Yaniv I, Ben-Ari J, Gamzu Z, Hoffer E et al Accidental busulfan overdose: Enhanced, drug clearance with hemodialysis in a child with Wiskott-Aldrich syndrome. Bone Marrow Transplant 2001; 27: 551-553.
26. Hassan M, Ljungman I, Ringdén O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulphan on the pharmaco-kinetics of cyclophoshamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000, 25: 915-924.
27. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944-950.
28. Takamia H, Tapaka. H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell population. Bone Marrow Transplant 2006; 37: 345-351.